Pharma BD Deal Intelligence
Ranks computed across 826 graded deals (Critic + Outcome Score both present).
AstraZeneca strategic collaboration with CSPC announced 30 January 2026; $1.2bn upfront, up to $3.5bn development/regulatory milestones plus commercial/sales…
AstraZeneca is expanding its prospects in cardiometabolic disease, paying $1.2 billion to begin a partnership on eight programs that include obesity drug…
In April 2026, AstraZeneca closed the previously announced new strategic collaboration agreement with CSPC Pharmaceuticals... The $1.2bn upfront, the majority…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
AstraZeneca licensed up to eight experimental obesity and diabetes medications from CSPC Pharmaceutical Group, including the long-acting GLP-1R/GIPR agonist SYH2082 and three preclinical programs using CSPC's peptide discovery and LiquidGel once-monthly injectable technology. CSPC received $1.2B upfront, with up to $3.5B in R&D milestones and $13.8B in sales milestones plus royalties. AstraZeneca gets exclusive global rights outside Greater China.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / CSPC Pharmaceutical Group Ltd. (this deal) | 2026 | $18.5B | 61 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
| AstraZeneca PLC / CinCor Pharma Inc. | 2023 | $1.8B | 78 |
← Browse all deals · How we score deals
More: 2026 deals · AstraZeneca PLC deals · Metabolic deals